Table 2.
Clinical Outcomes by Antimicrobial Treatment for Vancomycin-Resistant Enterococcus Bloodstream Infection
| Outcome | Linezolid (n = 319) | Daptomycin (n = 325) | Risk Ratio (95% CI) | P Value |
|---|---|---|---|---|
| Treatment failure | 214 (67.1) | 178 (54.8) | 1.37 (1.13–1.67) | .001 |
| 30-day all-cause mortality | 137 (42.9) | 109 (33.5) | 1.17 (1.04–1.32) | .014 |
| Microbiologic failurea | 23 (14.6) | 15 (6.4) | 1.10 (1.02–1.18) | .011 |
| 60-day VRE-BSI recurrence | 80 (25.1) | 72 (22.2) | 1.04 (.96–1.14) | .347 |
| Early (7-day) mortality | 41 (12.9) | 23 (7.1) | 1.07 (1.01–1.12) | .016 |
| Hospital length of stay, d, median (IQR) | 14 (7–25) | 12 (6–25) | … | .228 |
| Duration of bacteremia, d, median (IQR) | 4 (2–7) | 3 (2–5) | … | .033 |
Data are presented as No. (%) unless otherwise specified. Reference group: linezolid treatment.
Abbreviations: CI, confidence interval; IQR, interquartile range; VRE-BSI, vancomycin-resistant Enterococcus bloodstream infection.
a Percentages among those with ≥1 follow-up blood culture drawn during treatment period (linezolid, n = 157; daptomycin, n = 233).